Selection of PALF patients. The PALF study included patients younger than 18 years of age who met the following entry criteria: 1) no known evidence of chronic liver disease, 2) biochemical evidence of acute liver injury and 3) hepatic-based coagulopathy (not corrected with vitamin K) defined as a prothrombin time (PT) ≥ 15 s or international normalized ratio (INR) ≥1.5 in the presence of clinical hepatic encephalopathy (HE), or PT ≥20 s or INR ≥2.0 regardless of the presence or absence of HE.
MaTErIaLS aND METHODS
Selection of PALF patients. The PALF study included patients younger than 18 years of age who met the following entry criteria: 1) no known evidence of chronic liver disease, 2) biochemical evidence of acute liver injury and 3) hepatic-based coagulopathy (not corrected with vitamin K) defined as a prothrombin time (PT) ≥ 15 s or international normalized ratio (INR) ≥1.5 in the presence of clinical hepatic encephalopathy (HE), or PT ≥20 s or INR ≥2.0 regardless of the presence or absence of HE.
STaTISTICaL aNaLYSIS
We plotted the time courses of 27 mediators, shown as box plots representing the 25 th and 75 th percentiles, with a line at the median and error bars defining the 10 th and 90 th percentiles. The median of each inflammatory mediator across time points was calculated for each participant. A Kruskal-Wallis analysis of variance (ANOVA) on ranks was used to test whether the distributions of these median values for each inflammatory mediator were the same across the three outcome groups using SAS® 9.3 (SAS Institute).
Supplementary Figure S1 . Schematic of the statistical and computational methods and the rationale for their use in the present study. See details in Materials and Methods.
Supplementary Figure S2 . Time-dependent release of inflammatory mediators in PALF patients. Serum samples from PALF spontaneous survivors (S, n = 61 patients), nonsurvivors (NS, n = 12 patients), and liver transplant recipients (LTx, n = 28 patients) were assayed for 27 inflammatory mediators as described in Materials and Methods. Box plots represent the 25 th and 75 th percentiles, with a line at the median and error bars defining the 10 th and 90 th percentiles.
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Supplementary Figure S4 . Dynamic Bayesian network (DBN) analysis of circulating inflammatory mediators in PALF patients (agematched survivors versus nonsurvivors). Circulating inflammatory mediators in serum samples from PALF spontaneous survivors (S, n = 45 patients) that closely matched nonsurvivors (NS, n = 12 patients) were measured and DBN was performed as described in Materials and Methods. Inflammatory mediators are shown as nodes, and the arrows connecting them suggest an influence of one mediator on the one(s) it is connected to. The arrows do not distinguish positive from negative influences. Semicircular arrows suggest either positive or negative feedback of a given mediator on itself.
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